Simien & Simien, LLC


(800) 374-8422

Click To Call
Update: Simien & Simien is open and we are here to help you as we know your needs do not stop. The firm is currently open and operating. In light of current public health concerns, please know that we are following all health guidelines to protect both our team and our clients. We are offering virtual meetings by request.

GAO Report Finds Gaps in the FDA's oversight of Drug Safety

The Government Accountability Office released a report last week that summarized a list of shortcomings in how the Food and Drug Administration tracks drug safety issues.

In recent years, the FDA has sped up the process of approving many new drugs through expedited programs. Over 1,000 expedited requests were received from October 2006 to December 2014. Just last year, the FDA approved 45 new drugs.

This was the highest number of drugs approved in 19 years, with half of those drugs receiving specialized reviews so that they could reach the market faster.

As new drugs continue to be expedited, the GAO found that the FDA often fails to properly track important safety issues of those drugs.

Between 2008 and 2013, the FDA was late in reviewing more than half of the 1,400 follow up studies it had required of drug manufacturers. These post-market studies are crucial in finding out important safety issues that arise after patients start taking the drugs. These shortcomings could ultimately put more consumers at risk.

Furthermore, the GAO reported that many of the potential safety issues had not yet been uploaded to the FDA's drug archival tracking system. In interviews, the FDA told the Government Accountability Office that, "it had prioritized identifying, assessing and addressing potential safety issues over administrative tracking," due to the extensive workload of its review staff.

The Department of Health and Human Services says that the FDA is currently conducting evaluations in order to improve its computerized tracking system for reviewing drugs. The GAO recommends a complete overhaul of the FDA's database, so that information can be tracked more efficiently and accurately.

If you or someone you know has suffered due to a dangerous prescription drug, the defective product attorneys at Simien and Simien, LLC will fight to get you the justice you deserve. Our personal injury lawyers will work to get you the maximum compensation and closure that you are entitled to have.

No Comments

Leave a comment
Comment Information
FindLaw Network

Free Case Evaluation

Bold labels are required.

Contact Information

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.


Privacy Policy

If you are looking for a law firm that has knowledge and experience, you will find it with Simien & Simien, LLC.

Free Case Evaluation


Baton Rouge
7908 Wrenwood Blvd
Baton Rouge, LA 70809

Toll Free: 800-374-8422
Phone: 225-224-2222
Fax: 225-932-9286
Map & Directions

Lake Charles
Capital One Tower
Suite 1270
One Lakeshore Dr.
Lake Charles, LA 70629

Toll Free: 800-374-8422
Phone: 337-436-2121
Map & Directions

New Iberia
424 West Main St
New Iberia, LA 70560

Toll Free: 800-374-8422
Phone: 337-551-4242
Map & Directions

Houston Office
3730 Kirby Drive
Suite 1200
Houston, TX 77098

Toll Free: 800-374-8422
Map & Directions

New Orleans Office
1615 Poydras Street
Suite 900
New Orleans, LA 70112

Toll Free: 800-374-8422
Map & Directions

Nationwide (800) 374-8422